Primer: Ascletis Pharma (1672 HK) - May 2026
Ascletis is undergoing a critical strategic pivot from its legacy Hepatitis C (HCV) franchise, which has seen revenues collapse, to a high-risk,...
88 Views
Ascletis Pharma (1672 HK): Pipeline Not Appealing Enough to Make the Placement Attractive
Ascletis Pharmais placing ~69M shares at the price of HK$12.18 per share to raise HK$835M to fund global Phase 3 trials of small molecule oral GLP...
141 Views
APAC Healthcare Weekly (May 3) – Simcere, Beigene, Otsuka, Kyowa Kirin, Sun Pharma
NMPA accepted Simcere’s resubmitted NDA for Rademikibart. Beigene got FDA’s priority review for label expansion of Tevimra. Sun Pharma is acquiring...
242 Views
APAC Healthcare Weekly (April 12) – Wuxi XDC, Xuanzhu Biopharma, Shionogi, ABL Bio, PharmaEssentia
Wuxi XDC inked deal with Akari Therapeutics. Xuanzhu Bio entered licensing deal with Boston Oncology. Shionogi secured $119M BARDA contract for...
304 Views
China Healthcare Weekly (Aug.24)-JD Health 25H1 Results, Hansoh Placement, Ascletis Pharma Placement
JD Health 25H1 strong financial position and positive growth outlook support 3-4x P/S.Ascletis' potential valuation hinges on ASC30's clinical...
544 Views